Cherilyn Lai
Optometrist · Honolulu, HINPI 1811941743
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,266 of the $9,602 with a category attached, or 75.7%. 18 manufacturers reported payments, led by Alcon at 33.4% of the total. Reporting peaked in 2023 at $3,364 and has fallen 65.4% since, to $1,165 in 2025. Among optometrist clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 109 payments — averaging $88.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- Bausch & Lomb Americas Inc.$2K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$1K
- Aerie Pharmaceuticals, Inc.$598
- Amgen$517
- AbbVie$386
- plus $2K from 12 others
What the payments were for
- Consulting fees$5005%
- Travel & lodging$1,74718%
- Food & beverage$7,26676%
- Entertainment$891%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 26 | $3,204 |
| Bausch & Lomb Americas Inc. | 23 | $2,031 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 12 | $1,021 |
| Aerie Pharmaceuticals, Inc. | 2 | $598 |
| Amgen(2 entities) | 7 | $517 |
| AbbVie(2 entities) | 12 | $386 |
| LKC Technologies, Inc. | 3 | $372 |
| Glaukos Corporation | 3 | $332 |
| Coopervision Inc. | 5 | $242 |
| Kala Pharmaceuticals, Inc. | 4 | $188 |
| Tarsus Pharmaceuticals, Inc. | 3 | $163 |
| Dompe US, Inc. | 1 | $125 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $117 |
| Optos, Inc. | 2 | $89 |
| Novartis | 1 | $75 |
| Genentech USA, Inc. | 1 | $59 |
| Oyster Point Pharma, Inc. | 2 | $48 |
| Sun Pharmaceutical Industries Inc. | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INFUSE$1,010
- BIOTRUE ONE DAY$628
- Rocklatan$500
- DAILIES$418
- TOTAL30$400
- INFUSE MULTIFOCAL$300
- TEPEZZA$267
- VYZULTA$237
- Tecnis IOL$235
- Photrexa Viscous and Photrexa$174
- ZEN LENS$150
- INFUSE SVS$150
- ULTRA MULTIFOCAL TORIC$148
- iStent Trabecular Micro-Bypass System Model iS3$142
- Oxervate$125
- EYSUVIS$119
- CATALYS SYSTEM$117
- ULTRA$111
- MIEBO$106
- VUITY$100
How this compares
$9,602 in reported general payments places this provider in the 95th percentile of 310 optometrist providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 25 | $33,514 |
| VyzultaLatanoprostene Bunod | 25 | $17,250 |
| Latanoprost | 175 | $6,066 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 18 | $375 |
| Dorzolamide Hcl | 15 | $282 |
| Timolol Maleate | 13 | $154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $386 | $33,51425 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $2,031 | $17,25025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 310 optometrist providers in Hawaii.
Other optometrist in Honolulu
- Patricia IchimuraHonolulu$11K
- Lillian TakamuraHonolulu$11K
- Brian TeruyaHonolulu$9K
- Derrick AbeHonolulu$9K
- Jennifer TeruyaHonolulu$9K
- Malia KuniokaHonolulu$9K
- Leslie PoonHonolulu$8K
- Chris YamamotoHonolulu$8K
- Rodney FongHonolulu$8K
- Nicole YokoyamaHonolulu$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.